India, Feb. 24 -- Takeda Pharmaceutical Co. Ltd. (TKPHF.PK,TAK) announced on Monday that the European Medicines Agency or EMA has approved an additional 2 mL pre-filled pen option for Takhzyro or Lanadelumab. This approval is for the subcutaneous administration in adolescents, aged 12 years and above, and adult patients with recurrent hereditary Angioedema.
The company said that at present, Takhzyro is approved as 150 mg solution for injection in pre-filled syringe, 300 mg solution for injection in pre-filled syringe, and 300 mg solution for injection in vial. This latest approval for an additional subcutaneous administration option, i.e, the Takhzyro 300 mg solution for injection in pre-filled pen, containing 300 mg of Lanadelumab in 2 mL...